Hints and tips:
Related Special Reports
...German pharma group Boehringer Ingelheim is commercialising a Zealand treatment for both obesity and liver disease that is set to launch by 2028....
...Boehringer Ingelheim is building a new manufacturing plant but, says Dias of the EMA, “you don’t build a new site overnight”....
...The initial list of 10 drugs to face price negotiations includes a diabetes pill called Jardiance sold by Boehringer Ingelheim and Eli Lilly; a medicine to prevent strokes called Eliquis made by Pfizer and...
...The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim....
...However, its animal health division has observed the dangers of livestock developing resistance to drugs — something that then also threatens humans....
...Drugmakers GSK and Boehringer Ingelheim are now rationing inhalers, according to Premier....
...The proposed deal will create the second-biggest player in the animal medicines sector by revenues, leapfrogging Merck and Boehringer Ingelheim, but remaining behind Zoetis, the industry leader that was...
...Ingelheim, after it received approval....
...In 2017, Brainomix partnered with drugmaker Boehringer Ingelheim to offer its software in 1,500 stroke clinics across Europe....
...Another company, Boehringer Ingelheim of Germany, remains in patent litigation with AbbVie and has no plans for a European launch, despite its medicine being approved for sale in the EU....
...It could choose to spin off the unit — as it did in 2013 with its animal health business Zoetis. It could keep it....
...The move comes less than three years after Lilly bought Novartis’s animal health unit for $5.4bn and 10 months after it acquired an animal vaccines division from Boehringer Ingelheim, which helped the group...
...Addyi was first developed as an antidepressant in the 1990s by Boehringer Ingelheim, the German pharmaceuticals group, but failed to make it through clinical trials....
...Boehringer Ingelheim, Europe’s biggest private drugmaker, hired Simone Menne as chief financial officer from airline Lufthansa....
...Sanofi has been working to streamline its business and in June completed an asset swap deal to exchange its animal health business with Boehringer Ingelheim’s consumer healthcare business....
...Sanofi has also been working to streamline its business and in June completed an asset swap to exchange its animal health business with Boehringer Ingelheim’s consumer healthcare business....
...Even so, the big multinationals — under pressure to focus — have been hiving off their animal medicine arms: Novartis to Eli Lilly; Sanofi of France to Boehringer Ingelheim....
...its recently announced $885m acquisition of Boehringer Ingelheim Vetmedica’s US feline, canine and rabies vaccines portfolio....
...Andreas Barner, chairman of Boehringer Ingelheim said: Boehringer Ingelheim Animal Health is and will stay strongly committed to bringing novel, innovation driven solutions to veterinarians and animal owners...
...Sanofi last month completed a €22.8bn asset swap with Boehringer Ingelheim, which allowed the French group to trade its animal health unit and gain a new consumer-health focused business as well as a €4.7bn...
...Samsung Biologics ranks third behind Lonza of Switzerland and Boehringer Ingelheim of Germany....
...Sanofi has entered exclusive talks with Boehringer Ingelheim over an €18bn asset exchange that would see the French drugmaker swap its animal health unit for the German company's consumer health business...
...Boehringer would become the second largest company in animal health....
...GlaxoSmithKline and Novartis swapped oncology and vaccine assets in 2015; on Tuesday, Sanofi and Boehringer Ingelheim said they were in talks about swapping their animal and consumer health divisions....
...The first was an €18bn asset swap with Boehringer Ingelheim agreed last December, which, once completed, will see Sanofi trade its animal health unit for the German group’s consumer health business....
International Edition